Kornimate/medical-research-clean huggingface dataset:
genetic predisposition of coronary artery disease -- the corogene-study

Conditions: Coronary Disease; Inflammation

Summary: the aim of this study is to identify genetic loci,or gene variations contributing to inflammation and to the development of chd. we will compare coronary angiogram results to genetic findings within coronary artery disease patients and in patients with normal coronaries.

coronary artery disease (cad) is a chronic inflammatory disease, progression of which may be accelerated by immunological mechanisms. genes involved in regulation of inflammation and protection against infectious agents may affect picture of the disease . major histocompatibility complex (mhc) region carries genes involved in innate and adaptive immunity and inflammation. we have for the first time, identified genetic factors located in hla region, showing several fold risk for disease predisposition likely forming an important component to explain the high incidence of coronary heart disease in the finnish population. the aim of this study is to rerun our preliminary results, and further identify genetic loci, or gene variations contributing to the development of chd. the strategy is to collect altogether 5000 patients assigned to coronary angiogram in helsinki university central hospital. we will compare the angiogram results to genetic findings first in patients with normal coronaries, and in patients with different stages of chd. secondly we will compare phenotypic changes in inflammation and try to find out if the phenotype differs in different genotypes. thirdly we will collect patients from hospital discharge registry, and compare mortality and morbidity results in different gene groups. finally, we aim to record echocardiograms of the aortic valves in altogether 3500 consecutive patients undergoing coronary angiography. we try to identify genetic loci and gene variations contributing to the fibrosis and calcification of the aortic valve. the results of the study provide a possibility to develop a gene test to recognize patients at risk at its early stage, and needing for preventive medicine.

Eligibility criteria:
inclusion criteria: * patient assigned to coronary angiogram exclusion criteria: * inability to give informed consent

Keywords: coronary disease inflammation genetics hla antigens aortic valve
a registered cohort study of immune-mediated neuropathies

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Summary: this study will provide further insights into the natural course of the disease about immune-mediated neuropathies including clinical features，progression, related antibody spectrum and drug treatment effect.


Eligibility criteria:
inclusion criteria: - 1. outpatient or inpatient 2. meet the diagnostic criteria of various inflammatory peripheral neuropathy. 3. voluntary participation and informed consent signed by the applicant or his/her family. 4. age 18 or above exclusion criteria: 1. severe complications 2. poor prognosis (\<1 year survival) 3. severe mental disorder and inability to cooperate with the examination. 4. age less than 18
pcsk9 inhibitor and pd-1 inhibitor in patients with metastatic, refractory to prior anti pd-1 non-small cell lung

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: pcsk9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface mhc class 1 molecules. this study will evaluate if combining the anti-pcsk9 antibody alirocumab with the anti-pd-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.


Eligibility criteria:
inclusion criteria: * histologically documented recurrent and/or metastatic non-small cell lung cancer * progression after prior pd-1 directed therapy (as monotherapy or in combination with chemotherapy and/or anti-ctla4, or anti-vegf agents) - defined as investigator assessed progression from prior treatment * if molecularly altered nsclc including egfr, alk, ros1, met exon 14, ret, braf, ntrk, progression on prior targeted therapy is required * measurable disease by recist 1.1 * ecog performance status 0 or 1 * signed written informed consent * minimum of 4 weeks from any other experimental anti-cancer therapies or prior pd-1 treatment * meet all the laboratory criteria per protocol exclusion criteria: * prior treatment with pcsk9 inhibitors * cardiac issues including mi, uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications. * uncontrolled diabetes mellitus, defined as hba1c \> 10 * major surgery less than 4 weeks prior to study enrollment * another malignant condition diagnosed within 3 years of study enrollment * intolerance to prior pd-1/l1 treatment including discontinuation for severe or recurrent severe toxicity (including myocarditis or other myocardiotoxity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyperthyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, guillain-barre, myositis/polymyositis, hepatitis, type 1 diabetes, thrombocytopenia) or developed an immune checkpoint blockade related immune adverse event that was refractory to steroids and required additional systemic immunosuppressive medication. * known history of hiv seropositivity or known acquired immunodeficiency syndrome (aids) * additional exclusion criterion as per listed in the protocol
return of actionable variants empirical study

Conditions: Familial Hypercholesterolemia

Summary: this is a genomic implementation project with ancillary studies to understand the impact on patients' health and well-being of returning genomic results to them and depositing those results in the medical record.

study participant dna samples will be sequenced for 109 genes of interest along with genotyping of select polymorphisms. genetic tests will be performed in a clinical laboratory improvement amendments (clia) certified lab (baylor human genome sequencing laboratory). selected results (pathogenic/likely pathogenic) will be returned to participants by a genetic counselor and deposited into the electronic health record (ehr).

Eligibility criteria:
inclusion criteria: * moderate to severe hypercholesterolemia, elevated triglycerides, or colon polyps * resident of southeast minnesota area * able to provide informed consent * current participant in the mayo clinic biobank (08-007049, cerhan pi), the vascular disease biorepository (08-008355, kullo pi), or the study of the genetic determinants of peripheral artery disease (pad) (06-002911, kullo pi) with blood derived dna available exclusion criteria: * pregnant women will be allowed to enroll in the study. this is not an interventional study and there will be no risk to the mother or neonate. other vulnerable study populations will be excluded.
application of circulating exosomes in early diagnosis and prognosis evaluation after intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage；Circulating Exosomes

Summary: the purpose of this study is to observe the relationship between the changes of circulating exosomes and the development and outcome of the disease in patients with intracerebral hemorrhage, and to search for early serum markers and potential intervention targets for disease monitoring in patients with intracerebral hemorrhage


Eligibility criteria:
inclusion criteria: 1. no systematic treatment was given before admission; 2. the patients were diagnosed with cerebral hemorrhage, and had imaging evidence; 3. the age was more than 18 years old; 4. the patient or family member agrees to sign the informed consent. exclusion criteria: 1. hematoma is caused by secondary factors (intracranial tumor, arteriovenous malformation or aneurysm); 2. bleeding into the ventricle; 3. multiple cerebral hemorrhage; 4. the patient did not receive treatment in our hospital; 5. severe disability, dementia, or organ dysfunction before onset 6. coagulopathy or long-term use of anticoagulants 7. hematoma affects brain stem 8. subjects refused to participate
investigation of cervix tumor oxygenation and microvasculature using magnetic resonance techniques

Conditions: Cervix Cancer

Summary: in cervix cancer tumor oxygen levels and fluid pressure in the tumor have been shown to be related to patient outcome. analysis of the way tumors enhance after intravenous contrast injection using mri and ct can be used to determine parameters that relate to tumor blood vessels. in this study we hope to determine if there is a relationship between the enhancement of cervix cancer on mri and ct and tumor oxygen levels and interstitial fluid pressure. if such a relationship exists then it could help improve the care of patients wiht cervix cancer by allowing for more aggressive therapy of patients with cancer that have more ominous imaging characteristics

mri is already used routinely in the radiation planning and staging of carcinoma of the cervix. prognostic factors such as t-stage (local extent), tumor size and lymphadenopathy are routinely obtained from mri, however some prognostic parameters can only be obtained invasively. tumor oxygenation correlates with prognosis and response to treatment in patients undergoing radiotherapy for carcinoma of the cervix. interstitial fluid pressure (ifp) has been shown to correlate with tumor oxygenation as well. currently the only way to measure these parameters is by using an invasive technique which involves the placement of probes into the tumor and obtaining multiple measurements. recent studies have shown that a specific mri pulse sequences may be able to measure the oxygenation in the microcirculation. a second way of assessing the tumor microvasculature and perfusion is based on the behavior of intravenous contrast agents routinely used in the mri examination. estimates of blood volume, and capillary permeability can be made by mathematically modeling the kinetics of an mri contrast agent. similar measurements can be performed with ct. a total of 60 patients will be investigated. additional images will be obtained from these patients after their routine mri examination. one set of images is designed to measure a parameter that correlates with tumor oxygen levels. the second set of images will be obtained after the injection of intravenous contrast agent. using mathematical models a number of parameters will be extracted and correlated with ifp and tumor oxygen measurements.

Eligibility criteria:
inclusion criteria: * cervix cancer intended for radiation therapy exclusion criteria: * contraindication to contrast enhanced mri and ct * prior therapy for cervix cancer * prior pelvic radiation
testing of the apnea prevention device

Conditions: Respiratory Depression; Elective Surgery

Summary: this study is designed to test the ability of a computer-based algorithm to detect and intervene in cases of narcotic-induced respiratory depression.


Eligibility criteria:
inclusion criteria: * elective surgical patients exclusion criteria: * refusal to consent to study
study on the efficacy and safety of conversion therapy in patients with initially unresectable hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: to evaluate the efficacy and safety of conversion therapy in patients with initially unresectable hepatocellular carcinoma (uhcc).

to evaluate the efficacy and safety of conversion therapy in patients with initially unresectable hepatocellular carcinoma (uhcc). exon sequencing, 16srrna sequencing and immunohistochemistry were used to verify the protein expression, revealing the mechanism of tumor occurrence and development from the genome level, and providing reference for immunotherapy, targeted drug use and curative effect evaluation of tumors.

Eligibility criteria:
inclusion criteria: * ≥ 18 years old, gender is not limited; * patients with radiographically or pathologically confirmed, unresectable advanced hepatocellular carcinoma; * at least one measurable lesion according to the mrecist criteria as the target lesion; * no prior immunotherapy, including but not limited to anti-ctla-4, anti-pd-1, and anti-pd-l1 antibodies; * patients with an ecog score of 0-2 were included according to the activity status score scale developed by the eastern cooperative oncology group (ecog) in the united states; * child-pugh liver function is graded as a or b. exclusion criteria: * have a history of immunodeficiency, or have other acquired or congenital immunodeficiency diseases; * have other malignancies; * presence of any active autoimmune disease or history of autoimmune disease (including, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism), or known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, or other patients who are considered by the investigator to have an impact on study treatment; * long-term heavy use of corticosteroids or other immunomodulators; * serious illness in combination with other systems; * received a live or attenuated vaccine within 30 days prior to the first dose, or plans to receive a live or attenuated vaccine during the study, excluding the new crown vaccine; * known human immunodeficiency virus (hiv) infection; * have participated in other therapeutic clinical studies; * incomplete clinical data.
thyroid dysfunction in patients with major psychiatric disorders

Conditions: Thyroid Dysfunction

Summary: thyroid dysfunction in major psychiatric disorders in psychiatric patients admitted to psychiatric unit of assiut university hospital

thyroid hormones play a key role in the development, metabolism and functioning of many organs and have a profound influence on the human brain and behaviour. the coexistence of thyroid insufficiency with mental disorders was recognized . mental disorders accounted for 6 of the 20 leading causes of disability worldwide for the most productive section of the population.thyroid diseases can present with various neuropsychiatric manifestations which include mood, anxiety, psychotic, and cognitive disorders.thus, thyroid function tests are routinely checked in psychiatric patients, while dealing with neurocognitive or neuropsychiatric manifestations,thyroid disorders should be ruled out by appropriate thyroid function tests which include thyroid-stimulating hormone (tsh), free t3, free t4 and reverse t3.multiple studies on the prevalence of thyroid dysfunctions on psychiatric patients in different populations were done and reported .the presence of thyroid dysfunction in patients with schizophrenia-spectrum disorder as well as mood disorders .mental disorders merge highly with thyroid disease.bio-psycho-social medical model are important for treatment of mental disorders associated with thyroid dysfunction .till now, there is no literature on the rates of thyroid dysfunction among psychiatric patient in our population in assiut university hospital which can be helpful in the proper management of the cases.

Eligibility criteria:
inclusion criteria: * patients with major psychiatric disorders admitted to psychiatric unit of neuropsychiatry department of assiut university hospital in egypt. exclusion criteria: * pregnant or lactating females * patients on estrogen therapy or contraceptive * patients on carbamazepine, oxcarbazepine, phenytoin
a study of sex differences in neurocirculatory control

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to investigate potential sex differences in neurocirculatory control of blood pressure in patients with untreated obstructive sleep apnea (osa).


Eligibility criteria:
inclusion criteria: * 20-70 years of age exclusion criteria: * coronary artery disease * heart failure * pregnancy * copd * diabetes * ckd * sleep disorders other than osa * shift workers * individuals who typically go to sleep after midnight * individuals who traveled across ≥2 time zones within one week of study visits * bmi ≥40.0kg/m2 * use of nicotine-containing products within the two years preceding study visits * use of allopurinol, proton pump inhibitors, or other medications/supplements which interfere with outcome measures
bioequivalency study of exemestane 25 mg tablet under fed conditions

Conditions: Breast Cancer

Summary: the objective of this study was to prove the bioequivalence of exemestane 25 mg tablet under fed conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to exemestane or any comparable or similar product.
post sars-cov-2 disease anesthesia events

Conditions: Intraoperative Hypertension; Pain Threshold; Postoperative Pain; Postoperative Hypoxemia

Summary: estimating and recording the rate of occurrence of pulmonary and cardiovascular complications during the perioperative period in patients with past covid infection


Eligibility criteria:
inclusion criteria: * all patients above 18 years with past history of covid-19 during past 6 months undergoing surgery exclusion criteria: * hemodynamically unstable patients requiring oxygen therapy

Keywords: sars-cov-2 anesthesia
enhancing rural health via cardiovascular telehealth for rural patients implementation (e-victors)

Conditions: Cardiovascular Diseases; Acute Coronary Syndrome

Summary: this pre-post study will evaluate the implementation of a cardiovascular telehealth platform, which will connect experts from the wake forest university health sciences (wfuhs) tertiary care center with wilkes county emergency medical services (wc-ems) system, wilkes medical center emergency department (ed), and the wilkes county health department public health community clinic (phcc) to improve cardiovascular care in this rural community.

this program aims to improve cardiovascular care for patients in wilkes county by implementing a cardiovascular telehealth program designed to; a) assist wc- ems paramedics with the early risk stratification (electrocardiogram (ekg) interpretation, vital signs, and risk scores), treatment, and transportation destination decisions in patients with acute chest pain or dyspnea, b) support wilkes medical center (wmc) emergency department (ed) providers (physicians and advanced practice clinicians) in the evaluation, management, and disposition of patients with acute cardiovascular symptoms, and c) provide consultative expertise to the primary health care centers (phcc) for patients seen following an ems or ed encounter for cardiovascular symptoms.

Eligibility criteria:
inclusion criteria: * age \> 18 years at time of index encounter * cardiovascular symptoms (chest discomfort or dyspnea consistent with possible acs) as indicated by the treating provider exclusion criteria: * age \<18 * traumatic chest pain * dyspnea that is clearly from a non-cardiac etiology * patients with hemodynamic instability sbp \ 160 or \<40 bpm * patients requiring intubation/mechanical ventilation

Keywords: acute chest pain telehealth implementation science rural health
incidence and risk factors of postoperative hypothermia in cardiac surgery

Conditions: Postoperative Hypothermia in Patients With Cardiopulmonary Bypass

Summary: background: postoperative hypothermia may result in relevant complications such as adverse cardiovascular events, wound infection, and coagulopathy with consecutive blood loss. patients with open cardiac surgery using cardiopulmonary bypass are particular at risk for hypothermia. the study of karalapillai and coworkers, analyzing a huge database incl. 43,158 patients with cpb, revealed 66% of them experiencing postoperative hypothermia during the first 24 hours and 0.3% longer than that. during cardiac surgery great parts of body surface including wound surface are exposed. many of these patients receive large amounts of infusions and transfusions, and undergo hemodilution during cpb, which may additionally contribute to development of hypothermia. objective of the planned study is to find out incidence and duration of postoperative hypothermia and also risk factors for hypothermia in cardiac patients. further objective is the incidence of postoperative complications and its relation to postoperative core temperature. methods: a retrospective chart review 780 patients who had been underwent cardiac surgery with cpb included are patients ≥ 18 years old. excluded are patients with preoperative hyperthermia (\> 37.8 °c) and hypothermia (\> 36 °c). the following parameters will be recorded: temperature is measured at icu after arrived and after 6 hours which is primary outcome, biometric data include age, sex, body weight, height, asa physical status, surgical procedure includes emergency cases, anesthetic and surgical (bypass-) times, infusion/transfusion-regimen, blood loss and urine output, coolest temperature during bypass, method of temperature protection, and the outcome of operation . all data will be described in number and percent and pearson chi-square method will be used for analyze correlation between hypothermia and risk factor . p-value \<0.05 will be defined to significant.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old exclusion criteria: * patients with preoperative hyperthermia (\> 37.8 °c) and hypothermia (\< 36 °c).
move for surgery - a novel preconditioning program

Conditions: Lung Cancer, Nonsmall Cell

Summary: lung cancer is the leading cause of cancer death in canada. most patients with this cancer will undergo treatment with major chest surgery that is associated with serious complications. as many as 50% of patients will suffer respiratory complications after surgery, keeping them in the hospital for extended periods of time. these long hospitalizations have a dramatic negative effect on the lives of those people, in addition to a large cost burden on our healthcare system. traditionally, patients who suffer from complications are treated with rehabilitation after the complications have occurred. but what if complications can be prevented before they happen? having major chest surgery imposes great stress on the human body, one that is equivalent to running a marathon. analogous to training before completing a marathon, the investigator designed move for surgery (mfs), a novel preconditioning program that encourages and empowers patients to improve their health prior to surgery. the investigator aims to demonstrate that patients who train with move for surgery will have lower respiratory complication rates, will recover better, and will leave the hospital sooner than their counterparts.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * clinical stage i, ii, or iiia non-small cell lung cancer (nsclc) * candidates for thoracic surgery, as determined by the operating surgeon exclusion criteria: * clinical stage iiib or iv nsclc * patients with affected mobility (wheelchair, walker) * patients who use oxygen at home